Browse studies

Find your next paid study

33 recruiting studies matching your filters

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by c…

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06507930

Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and pre…

PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more

Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT05216432

Observational

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer

The goal of this clinical trial is to test the efficacy a new psychosocial symptom management intervention called ENGAGE for patients with Stage IV breast, pro…

Advanced Breast CancerAdvanced Prostate CancerAdvanced Lung Cancer+2 more

Estimated

~$10 – $6,250

Duke UniversityNCT06555588

Phase 2

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which t…

Breast NeoplasmsBreast CancerBreast Tumors+8 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT01042379

Phase 1

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in c…

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer

Estimated

~$10 – $8,750

Boundless Bio, Inc.NCT07408089

Phase 2

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (…

Breast CancerLocally Advanced Breast CancerCognitive Impairment+5 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06727773

Phase 1

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhan…

Breast CancerLocally Advanced Breast CancerNeoadjuvant Chemotherapy+3 more

Estimated

~$10 – $7,500

Alison StopeckNCT06220214

Phase 2

Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)

The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treat…

Advanced Breast Cancer

Estimated

~$10 – $6,250

Dartmouth-Hitchcock Medical CenterNCT05933395

Phase 1

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)

This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifun…

Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT06827613